You have accessJournal of UrologySexual Function/Dysfunction: Penis/Testis/Urethra: Benign Disease & Malignant Disease I1 Apr 2017PD49-01 ADJUVANT PELVIC RADIATION IS ASSOCIATED WITH IMPROVED SURVIVAL AND DECREASED DISEASE RECURRENCE IN PELVIC NODE-POSITIVE PENILE CANCER AFTER LYMPH NODE DISSECTION: A MULTI-INSTITUTIONAL STUDY Dominic Tang, Rosa Djajadiningrat, Gregory Diorio, Zhenjun Ma, Braydon Schaible, Mario Catanzaro, Dingwei Ye, Yao Zhu, Nicola Nicolai, Simon Horenblas, Peter Johnstone, and Philippe Spiess Dominic TangDominic Tang More articles by this author , Rosa DjajadiningratRosa Djajadiningrat More articles by this author , Gregory DiorioGregory Diorio More articles by this author , Zhenjun MaZhenjun Ma More articles by this author , Braydon SchaibleBraydon Schaible More articles by this author , Mario CatanzaroMario Catanzaro More articles by this author , Dingwei YeDingwei Ye More articles by this author , Yao ZhuYao Zhu More articles by this author , Nicola NicolaiNicola Nicolai More articles by this author , Simon HorenblasSimon Horenblas More articles by this author , Peter JohnstonePeter Johnstone More articles by this author , and Philippe SpiessPhilippe Spiess More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2225AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Few studies have examined the role of adjuvant radiation therapy (AXRT) in advanced penile squamous cell carcinoma. We sought to evaluate the association of pelvic AXRT with survival and recurrence for patients with penile cancer and positive pelvic lymph nodes (PLN) after lymph node dissection. METHODS Data were collected retrospectively across 4 international centers of patients with penile squamous cell carcinoma (PeCa) undergoing lymph node dissections from 1980 to 2013. 92 patients with positive PLN were analyzed. Variables recorded included age, stage, histological grade, PLN status, pelvic extranodal extension (ENE), chemotherapy status, disease-specific survival, overall survival, and recurrence. RESULTS 43% (n=40) patients received AXRT after a positive PLN dissection. Median follow up was 9.3 months (IQR 5.2-19.8). The median number of positive PLN was 2 (IQR 1-3). Patients receiving AXRT had an improved median overall survival (OS) of 12.2 months versus 8 months in those who did not receive radiation (p=0.0447). Median disease-specific survival (DSS) was 14.4 months versus 8 months in the AXRT and non-AXRT group respectively (p=0.0232). Patients not receiving AXRT was associated with worse OS (HR: 1.9; 95% CI: 1.11-3.26; p=0.0195) and DSS (HR: 2.08; 95% CI: 1.18-3.66; p=0.0112) on multivariable analysis. Median time to recurrence was 7.7 months versus 5.3 months in the radiation and non-radiation arm respectively (p=0.0425). Patients not receiving AXRT was also independently associated with higher overall recurrence on multivariable analysis (HR: 1.98; 95% CI: 1.15-3.42; p=0.0131). CONCLUSIONS AXRT is associated with improved OS and DSS, and decreased recurrence in this population of PeCa patients with positive PLN. Further studies with a prospective design and larger data sets are required to validate this finding. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e973 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Dominic Tang More articles by this author Rosa Djajadiningrat More articles by this author Gregory Diorio More articles by this author Zhenjun Ma More articles by this author Braydon Schaible More articles by this author Mario Catanzaro More articles by this author Dingwei Ye More articles by this author Yao Zhu More articles by this author Nicola Nicolai More articles by this author Simon Horenblas More articles by this author Peter Johnstone More articles by this author Philippe Spiess More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract